{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:13:27Z","timestamp":1788207207811,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PNRR\u2014M4C2-I1.3 Project PE_00000019 \u201cHEAL ITALIA\u201d"],"award-info":[{"award-number":["PNRR\u2014M4C2-I1.3 Project PE_00000019 \u201cHEAL ITALIA\u201d"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP I53C22001440006"],"award-info":[{"award-number":["CUP I53C22001440006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-026-02497-0","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:14:21Z","timestamp":1788203661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter 2 inhibitors are associated with reduced circulating activin A and modulation of BMP\/activin signaling in ischemic cardiomyopathy with high echocardiographic probability of pulmonary hypertension"],"prefix":"10.1007","author":[{"given":"Rosalinda","family":"Madonna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Del Boccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Borghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Biondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cufaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiana","family":"Pieragostino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Andreassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Mattii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Angelone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2497_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2024.07.030","author":"R Madonna","year":"2024","unstructured":"Madonna R, Biondi F, Ghelardoni S, D\u2019Alleva A, Quarta S, Massaro M. Pulmonary hypertension associated to left heart disease: phenotypes and treatment. Eur J Intern Med. 2024. https:\/\/doi.org\/10.1016\/j.ejim.2024.07.030.","journal-title":"Eur J Intern Med"},{"key":"2497_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116650","volume":"175","author":"R Madonna","year":"2024","unstructured":"Madonna R, Biondi F, Alberti M, Ghelardoni S, Mattii L, D\u2019Alleva A. Cardiovascular outcomes and molecular targets for the cardiac effects of Sodium- glucose cotransporter 2 inhibitors: a systematic review. Biomed Pharmacother. 2024Jun;175:116650. https:\/\/doi.org\/10.1016\/j.biopha.2024.116650.","journal-title":"Biomed Pharmacother"},{"issue":"2025","key":"2497_CR3","doi-asserted-by":"publisher","first-page":"6649731","DOI":"10.1155\/cdr\/6649731","volume":"21","author":"K Bhandari","year":"2025","unstructured":"Bhandari K, Qadri M, Dhakal R, Ghimire S, Jora G, Basyal S, et al. The impact of SGLT2 inhibitors on pulmonary artery pressures and pulmonary hemodynamics in patients with heart failure: a systematic review. Cardiovasc Ther. 2025Oct;21(2025):6649731.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"2497_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1124\/jpet.121.001251","volume":"384","author":"P Mone","year":"2023","unstructured":"Mone P, Lombardi A, Kansakar U, Varzideh F, Jankauskas SS, Pansini A, et al. Empagliflozin improves the MicroRNA signature of endothelial dysfunction in patients with heart failure with preserved ejection fraction and diabetes. J Pharmacol Exp Ther. 2023;384(1):116\u201322. https:\/\/doi.org\/10.1124\/jpet.121.001251.","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"2497_CR5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.122.058794","volume":"147","author":"E Born","year":"2023","unstructured":"Born E, Lipskaia L, Breau M, Houssaini A, Beaulieu D, Marcos E, et al. Eliminating senescent cells can promote pulmonary hypertension development and progression. Circulation. 2023;147(8):650\u201366. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.058794.","journal-title":"Circulation"},{"issue":"3","key":"2497_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11030571","volume":"11","author":"C Rocca","year":"2022","unstructured":"Rocca C, De Bartolo A, Granieri MC, Rago V, Amelio D, Falbo F, et al. The antioxidant selenoprotein T mimetic, PSELT, induces preconditioning-like myocardial protection by relieving endoplasmic-reticulum stress. Antioxidants (Basel). 2022;11(3):571. https:\/\/doi.org\/10.3390\/antiox11030571.","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"2497_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/cvr\/cvad009","volume":"119","author":"R Madonna","year":"2023","unstructured":"Madonna R, Moscato S, Cufaro MC, Pieragostino D, Mattii L, Del Boccio P, et al. Empagliflozin inhibits excessive autophagy through the AMPK\/GSK3\u03b2 signalling pathway in diabetic cardiomyopathy. Cardiovasc Res. 2023;119(5):1175\u201389.","journal-title":"Cardiovasc Res"},{"key":"2497_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2020.106807","volume":"135","author":"R Madonna","year":"2020","unstructured":"Madonna R, Pieragostino D, Rossi C, Guarnieri S, Nagy CT, Giricz Z, et al. Transplantation of telomerase\/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. Vascul Pharmacol. 2020;135:106807. https:\/\/doi.org\/10.1016\/j.vph.2020.106807.","journal-title":"Vascul Pharmacol"},{"key":"2497_CR9","doi-asserted-by":"publisher","first-page":"e70528","DOI":"10.1111\/jcmm.70528","volume":"29","author":"M Cabiati","year":"2025","unstructured":"Cabiati M, Biondi F, Ghelardoni S, Casieri V, Lionetti V, Sgalippa A, Del Ry S, Madonna R. Ambrisentan retains its pro-autophagic activity on human pulmonary artery endothelial cells exposed to hypoxia in an in vitro model mimicking diabetes. J Cell Mol Med. 2025;29:e70528. https:\/\/doi.org\/10.1111\/jcmm.70528.","journal-title":"J Cell Mol Med"},{"key":"2497_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/eci.70038","author":"R Madonna","year":"2025","unstructured":"Madonna R, Montemaggi E. Pulmonary hypertension and associated heart failure: new insights on emerging signalling pathways. Eur J Clin Invest. 2025. https:\/\/doi.org\/10.1111\/eci.70038.","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"2497_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3892\/ijmm.2020.4821","volume":"47","author":"J Zheng","year":"2021","unstructured":"Zheng J, Tan Q, Chen H, Chen K, Wang H, Chen Z, et al. LncRNA\u2011SNHG7\u2011003 inhibits the proliferation, migration and invasion of vascular smooth muscle cells by targeting the miR\u20111306\u20115p\/SIRT7 signaling pathway. Int J Mol Med. 2021;47(2):741\u201350. https:\/\/doi.org\/10.3892\/ijmm.2020.4821.","journal-title":"Int J Mol Med"},{"issue":"4","key":"2497_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5135","volume":"7","author":"M Gao","year":"2024","unstructured":"Gao M, Bhatia K, Kapoor A, Badimon J, Pinney SP, Mancini DM, et al. SGLT2 inhibitors, functional capacity, and quality of life in patients with heart failure: a systematic review and meta-analysis. JAMA Netw Open. 2024;7(4):e245135. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.5135.","journal-title":"JAMA Netw Open"},{"key":"2497_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106243","volume":"180","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Antonopoulos AS, Katsimichas T, Oikonomou E, Siasos G, Aggeli C, et al. The impact of SGLT2 inhibition on imaging markers of cardiac function: a systematic review and meta-analysis. Pharmacol Res. 2022;180:106243. https:\/\/doi.org\/10.1016\/j.phrs.2022.106243.","journal-title":"Pharmacol Res"},{"issue":"17","key":"2497_CR14","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1161\/CIRCULATIONAHA.120.052503","volume":"143","author":"ME Nassif","year":"2021","unstructured":"Nassif ME, Qintar M, Windsor SL, Jermyn R, Shavelle DM, Tang F, et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from the EMBRACE-HF trial. Circulation. 2021;143(17):1673\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052503.","journal-title":"Circulation"},{"issue":"10 Pt B","key":"2497_CR15","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jcmg.2016.12.024","volume":"10","author":"M Guazzi","year":"2017","unstructured":"Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, et al. RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging. 2017;10(10 Pt B):1211\u201321. https:\/\/doi.org\/10.1016\/j.jcmg.2016.12.024.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"2497_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","volume":"9","author":"YNV Reddy","year":"2024","unstructured":"Reddy YNV, Carter RE, Sorimachi H, Omar M, Popovic D, Alogna A, et al. Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2024;9(9):843\u201351. https:\/\/doi.org\/10.1001\/jamacardio.2024.1914.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2497_CR17","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1253\/circj.CJ-20-0341","volume":"84","author":"H Kayano","year":"2020","unstructured":"Kayano H, Koba S, Hirano T, Matsui T, Fukuoka H, Tsuijita H, et al. Dapagliflozin influences ventricular hemodynamics and exercise-induced pulmonary hypertension in type 2 diabetes patients- a randomized controlled trial. Circ J. 2020;84(10):1807\u201317. https:\/\/doi.org\/10.1253\/circj.CJ-20-0341.","journal-title":"Circ J"},{"issue":"16","key":"2497_CR18","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478\u201390. https:\/\/doi.org\/10.1056\/NEJMoa2213558.","journal-title":"N Engl J Med"},{"issue":"11","key":"2497_CR19","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1161\/01.CIR.0000120704.97934.41","volume":"109","author":"A Yndestad","year":"2004","unstructured":"Yndestad A, Ueland T, \u00d8ie E, Florholmen G, Halvorsen B, Attramadal H, et al. Elevated levels of activin A in heart failure: potential role in myocardial remodeling. Circulation. 2004;109(11):1379\u201385. https:\/\/doi.org\/10.1161\/01.CIR.0000120704.97934.41.","journal-title":"Circulation"},{"issue":"10","key":"2497_CR20","doi-asserted-by":"publisher","first-page":"1064290","DOI":"10.3389\/fcvm.2023.1064290","volume":"23","author":"SR Joshi","year":"2023","unstructured":"Joshi SR, Atabay EK, Liu J, Ding Y, Briscoe SD, Alexander MJ, et al. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure. Front Cardiovasc Med. 2023Feb;23(10):1064290. https:\/\/doi.org\/10.3389\/fcvm.2023.1064290.","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"2497_CR21","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1172\/JCI120847","volume":"128","author":"MK Culley","year":"2018","unstructured":"Culley MK, Chan SY. Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains. J Clin Invest. 2018;128(9):3704\u201315. https:\/\/doi.org\/10.1172\/JCI120847.","journal-title":"J Clin Invest"},{"key":"2497_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4939-1875-1_3","volume":"1241","author":"JP Rooney","year":"2015","unstructured":"Rooney JP, Ryde IT, Sanders LH, Howlett EH, Colton MD, Germ KE, et al. PCR based determination of mitochondrial DNA copy number in multiple species. Methods Mol Biol. 2015;1241:23\u201338. https:\/\/doi.org\/10.1007\/978-1-4939-1875-1_3.","journal-title":"Methods Mol Biol"},{"issue":"11","key":"2497_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1001\/jamacardio.2017.3683","volume":"2","author":"FN Ashar","year":"2017","unstructured":"Ashar FN, Zhang Y, Longchamps RJ, Lane J, Moes A, Grove ML, et al. Association of mitochondrial DNA copy number with cardiovascular disease. JAMA Cardiol. 2017;2(11):1247\u201355. https:\/\/doi.org\/10.1001\/jamacardio.2017.3683.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"2497_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22083-6","volume":"12","author":"H Lee","year":"2022","unstructured":"Lee H, Kim H, Jeon JS, Noh H, Park R, Byun DW, et al. Empagliflozin suppresses urinary mitochondrial DNA copy numbers and interleukin-1\u03b2 in type 2 diabetes patients. Sci Rep. 2022;12(1):19103. https:\/\/doi.org\/10.1038\/s41598-022-22083-6.","journal-title":"Sci Rep"},{"issue":"1","key":"2497_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-64997-3","volume":"14","author":"HG Chung","year":"2024","unstructured":"Chung HG, Yang PS, Cho S, Jang E, Kim D, Yu HT, et al. The associations of leukocyte telomere length and intermediary cardiovascular phenotype with adverse cardiovascular outcomes in the white population. Sci Rep. 2024;14(1):13975. https:\/\/doi.org\/10.1038\/s41598-024-64997-3.","journal-title":"Sci Rep"},{"issue":"3","key":"2497_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032708","volume":"13","author":"AM Salih","year":"2024","unstructured":"Salih AM, Galazzo IB, Menegaz G, Altmann A. Leukocyte telomere length and cardiac structure and function: a Mendelian randomization study. J Am Heart Assoc. 2024;13(3):e032708. https:\/\/doi.org\/10.1161\/JAHA.123.032708.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"2497_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1161\/CIRCULATIONAHA.114.013258","volume":"131","author":"N Mouraret","year":"2015","unstructured":"Mouraret N, Houssa\u00efni A, Abid S, Quarck R, Marcos E, Parpaleix A, et al. Role for telomerase in pulmonary hypertension. Circulation. 2015;131(8):742\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013258.","journal-title":"Circulation"},{"key":"2497_CR28","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.2147\/DMSO.S428560","volume":"16","author":"B Qin","year":"2023","unstructured":"Qin B. Can antidiabetic medications affect telomere length in patients with type 2 diabetes? A mini-review. Diabetes Metab Syndr Obes. 2023;16:3739\u201350. https:\/\/doi.org\/10.2147\/DMSO.S428560.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2497_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ejhf.950","volume":"20","author":"N van Boven","year":"2018","unstructured":"van Boven N, Kardys I, van Vark LC, Akkerhuis KM, de Ronde MWJ, Khan MAF, et al. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail. 2018;20(1):89\u201396. https:\/\/doi.org\/10.1002\/ejhf.950.","journal-title":"Eur J Heart Fail"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02497-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02497-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T19:14:22Z","timestamp":1788203662000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02497-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":29,"alternative-id":["2497"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02497-0","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PF is the founder and CEO of Pharmahungary Group, a group of R&D companies developing cardioprotective therapies and holding patents on cardioprotective molecules.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}